Brokerages forecast that Teleflex Incorporated (NYSE:TFX) will announce sales of $643.31 million for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Teleflex’s earnings. The highest sales estimate is $648.20 million and the lowest is $641.30 million. Teleflex posted sales of $609.67 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.5%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 7th.

On average, analysts expect that Teleflex will report full year sales of $2.60 billion for the current year, with estimates ranging from $2.59 billion to $2.60 billion. For the next year, analysts forecast that the company will post sales of $2.78 billion, with estimates ranging from $2.76 billion to $2.82 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Teleflex.

Teleflex (NYSE:TFX) last issued its quarterly earnings data on Thursday, August 1st. The medical technology company reported $2.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.59 by $0.07. Teleflex had a return on equity of 18.57% and a net margin of 10.78%. The business had revenue of $652.50 million during the quarter, compared to analysts’ expectations of $637.06 million. During the same period in the previous year, the firm posted $2.47 earnings per share. The company’s revenue was up 7.0% on a year-over-year basis.

Several brokerages have recently issued reports on TFX. ValuEngine cut shares of Teleflex from a “buy” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Co assumed coverage on shares of Teleflex in a report on Tuesday, June 11th. They issued an “outperform” rating and a $345.00 price objective for the company. Svb Leerink upped their target price on shares of Teleflex from $395.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. Needham & Company LLC reiterated a “buy” rating and set a $403.00 target price (up from $325.00) on shares of Teleflex in a report on Friday, August 2nd. Finally, Raymond James raised their price target on shares of Teleflex from $350.00 to $420.00 and gave the company a “strong-buy” rating in a research report on Friday, August 2nd. Three research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Teleflex has a consensus rating of “Buy” and an average target price of $374.45.

In other news, CFO Thomas E. Powell sold 7,500 shares of Teleflex stock in a transaction on Friday, September 6th. The shares were sold at an average price of $355.52, for a total transaction of $2,666,400.00. Following the completion of the sale, the chief financial officer now directly owns 18,197 shares of the company’s stock, valued at approximately $6,469,397.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Benson Smith sold 8,500 shares of the business’s stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $330.75, for a total transaction of $2,811,375.00. Following the transaction, the director now owns 85,300 shares of the company’s stock, valued at approximately $28,212,975. The disclosure for this sale can be found here. Insiders have sold 37,453 shares of company stock worth $12,679,692 over the last 90 days. Insiders own 2.36% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. Reilly Financial Advisors LLC acquired a new position in Teleflex in the second quarter valued at approximately $25,000. Quantamental Technologies LLC purchased a new position in shares of Teleflex in the 1st quarter valued at $26,000. Quadrant Capital Group LLC raised its stake in Teleflex by 82.8% during the 1st quarter. Quadrant Capital Group LLC now owns 117 shares of the medical technology company’s stock worth $33,000 after acquiring an additional 53 shares in the last quarter. Icon Wealth Partners LLC acquired a new stake in Teleflex during the 1st quarter worth $37,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Teleflex during the 2nd quarter worth $46,000. Institutional investors own 90.67% of the company’s stock.

NYSE:TFX traded down $2.45 on Friday, reaching $338.88. 467,302 shares of the company’s stock were exchanged, compared to its average volume of 333,671. The company has a quick ratio of 1.59, a current ratio of 2.52 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $16.47 billion, a price-to-earnings ratio of 34.23, a price-to-earnings-growth ratio of 2.31 and a beta of 1.00. The business has a fifty day moving average of $359.14 and a 200-day moving average of $318.55. Teleflex has a 52-week low of $226.02 and a 52-week high of $373.90.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 16th. Stockholders of record on Thursday, August 15th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date of this dividend is Wednesday, August 14th. Teleflex’s dividend payout ratio is presently 13.74%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Recommended Story: Blockchain

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with's FREE daily email newsletter.